LRMR
Larimar Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website larimartx.com
- Employees(FY) 26
- ISIN US5171251003
Performance
-6.11%
1W
+1.93%
1M
-42.25%
3M
+138.83%
6M
+62.2%
YTD
+100.0%
1Y
Profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
Investment Analysis Report: LRMR
Overview:
LRMR is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $561,117,440. In this report, we will conduct a comprehensive analysis of LRMR's financial health, valuation, earnings and revenue growth, profitability, op...
Technical Analysis of LRMR 2024-05-10
Overview:
In analyzing the technical indicators for LRMR stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining key metrics such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim to...
Recent News & Updates
- 2024-05-10 06:28
- 2024-05-09 07:00
- 2024-05-09 01:55
- 2024-05-08 19:00
- 2024-03-20 01:32
- 2024-03-14 16:05
- 2024-03-14 09:53
- 2024-03-14 05:32
- 2024-03-14 04:05
- 2024-03-11 16:05
- 2024-03-11 04:05
- 2024-03-06 16:05
- 2024-03-06 03:05
- 2024-02-20 00:47
- 2024-02-19 00:48
- 2024-02-16 16:20
- 2024-02-16 03:20
- 2024-02-14 06:15
- 2024-02-13 17:15
- 2024-02-13 16:18
- 2024-02-13 03:18
- 2024-02-12 07:00
- 2024-02-11 18:00
- 2023-12-09 07:29
- 2023-11-13 18:00
- 2023-11-01 04:05
- 2023-10-03 04:05
- 2023-08-31 04:05
- 2023-08-09 19:00
- 2023-08-06 21:22
Page 1 of 4
previousnext